-DOCSTART- -X- O
OBJECTIVE -X- _ O
: -X- _ O
The -X- _ O
present -X- _ O
study -X- _ O
aimed -X- _ O
to -X- _ O
analyze -X- _ O
clinical -X- _ B-Outcome
features -X- _ I-Outcome
and -X- _ I-Outcome
factors -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
treatment -X- _ I-Outcome
outcomes -X- _ I-Outcome
of -X- _ O
H7N9 -X- _ B-Patient
influenza -X- _ I-Patient
A -X- _ I-Patient
virus -X- _ I-Patient
infection. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
The -X- _ O
clinical -X- _ O
progress -X- _ O
in -X- _ O
18 -X- _ B-Patient
H7N9-infected -X- _ I-Patient
patients -X- _ I-Patient
was -X- _ O
monitored -X- _ O
and -X- _ O
recorded. -X- _ O
The -X- _ O
clinical -X- _ O
features -X- _ O
of -X- _ O
H7N9 -X- _ O
infection -X- _ O
were -X- _ O
noted -X- _ O
and -X- _ O
factors -X- _ O
associated -X- _ O
with -X- _ O
treatment -X- _ O
outcomes -X- _ O
were -X- _ O
analyzed -X- _ O
by -X- _ O
univariate -X- _ O
analyses. -X- _ O
RESULTS -X- _ O
: -X- _ O
The -X- _ O
average -X- _ O
ages -X- _ O
of -X- _ O
patients -X- _ O
in -X- _ O
recovered -X- _ O
and -X- _ O
critical -X- _ O
conditions -X- _ O
were -X- _ O
67.0±10.83 -X- _ O
years -X- _ O
and -X- _ O
72.75±12.0 -X- _ O
years -X- _ O
, -X- _ O
respectively. -X- _ O
Renal -X- _ B-Outcome
insufficiency -X- _ I-Outcome
developed -X- _ I-Outcome
more -X- _ I-Outcome
frequently -X- _ I-Outcome
in -X- _ I-Outcome
critically -X- _ I-Outcome
ill -X- _ I-Outcome
patients -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.023 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
The -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
traditional -X- _ I-Outcome
Chinese -X- _ I-Outcome
medicine -X- _ I-Outcome
( -X- _ I-Outcome
TCM -X- _ I-Outcome
) -X- _ I-Outcome
therapy -X- _ I-Outcome
was -X- _ I-Outcome
longer -X- _ I-Outcome
in -X- _ I-Outcome
recovered -X- _ I-Outcome
patients -X- _ I-Outcome
than -X- _ I-Outcome
in -X- _ I-Outcome
critically -X- _ I-Outcome
ill -X- _ I-Outcome
patients -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.01 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Laboratory -X- _ I-Outcome
tests -X- _ I-Outcome
showed -X- _ I-Outcome
that -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
C-reactive -X- _ I-Outcome
protein -X- _ I-Outcome
, -X- _ I-Outcome
serum -X- _ I-Outcome
creatinine -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
myoglobin -X- _ I-Outcome
were -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
in -X- _ I-Outcome
critically -X- _ I-Outcome
ill -X- _ I-Outcome
patients -X- _ I-Outcome
than -X- _ I-Outcome
in -X- _ I-Outcome
recovered -X- _ I-Outcome
patients -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.011 -X- _ I-Outcome
, -X- _ I-Outcome
0.04 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
0.016 -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Meanwhile -X- _ I-Outcome
, -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
all -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
subsets -X- _ I-Outcome
examined -X- _ I-Outcome
including -X- _ I-Outcome
total -X- _ I-Outcome
CD3 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
CD4 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
CD8 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
CD45 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T -X- _ I-Outcome
cells -X- _ I-Outcome
were -X- _ I-Outcome
lower -X- _ I-Outcome
in -X- _ I-Outcome
critically -X- _ I-Outcome
ill -X- _ I-Outcome
patients -X- _ I-Outcome
than -X- _ I-Outcome
in -X- _ I-Outcome
recovered -X- _ I-Outcome
patients -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.033 -X- _ I-Outcome
, -X- _ I-Outcome
0.059 -X- _ I-Outcome
, -X- _ I-Outcome
0.015 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
0.039 -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Logistic -X- _ I-Outcome
regression -X- _ I-Outcome
analysis -X- _ I-Outcome
demonstrated -X- _ I-Outcome
that -X- _ I-Outcome
C-reactive -X- _ I-Outcome
protein -X- _ I-Outcome
level -X- _ I-Outcome
, -X- _ I-Outcome
myoglobin -X- _ I-Outcome
level -X- _ I-Outcome
and -X- _ I-Outcome
TCM -X- _ I-Outcome
therapy -X- _ I-Outcome
duration -X- _ I-Outcome
were -X- _ I-Outcome
likely -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
treatment -X- _ I-Outcome
outcomes -X- _ I-Outcome
of -X- _ I-Outcome
H7N9 -X- _ I-Outcome
infection -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.032 -X- _ I-Outcome
, -X- _ I-Outcome
0.041 -X- _ I-Outcome
and -X- _ I-Outcome
0.017 -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
CONCLUSION -X- _ O
: -X- _ O
Elderly -X- _ B-Outcome
people -X- _ I-Outcome
may -X- _ I-Outcome
have -X- _ I-Outcome
increased -X- _ I-Outcome
risk -X- _ I-Outcome
for -X- _ I-Outcome
H7N9 -X- _ I-Outcome
virus -X- _ I-Outcome
infection. -X- _ I-Outcome
T -X- _ O
cell-mediated -X- _ O
responses -X- _ O
play -X- _ O
an -X- _ O
important -X- _ O
role -X- _ O
in -X- _ O
defense -X- _ O
against -X- _ O
the -X- _ O
H7N9 -X- _ O
virus. -X- _ O
C-reactive -X- _ B-Outcome
protein -X- _ I-Outcome
level -X- _ I-Outcome
, -X- _ I-Outcome
myoglobin -X- _ I-Outcome
level -X- _ I-Outcome
and -X- _ I-Outcome
TCM -X- _ I-Outcome
duration -X- _ I-Outcome
may -X- _ I-Outcome
be -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ O
treatment -X- _ O
outcomes -X- _ O
of -X- _ O
H7N9 -X- _ O
infection -X- _ O
. -X- _ O

